^
BIOMARKER:

EGFR L858R + EGFR T790M

i
Other names: EGFR, ERBB, ERBB1, Epidermal growth factor receptor
Entrez ID:
EGFR L858R + EGFR T790M
NSCLC
osimertinib + afatinib
Sensitive: B - Late Trials
EGFR L858R + EGFR T790M
NSCLC
erlotinib
Resistant: C3 – Early Trials
EGFR L858R + EGFR T790M
NSCLC
osimertinib
Sensitive: C3 – Early Trials
EGFR L858R + EGFR T790M
NSCLC
afatinib
Sensitive: C3 – Early Trials
EGFR L858R + EGFR T790M
NSCLC
gefitinib
Resistant: C3 – Early Trials
EGFR L858R + EGFR T790M
Lung Non-Small Cell Squamous Cancer
gefitinib
Resistant: C4 – Case Studies
EGFR L858R + EGFR T790M
LUAD
gefitinib
Resistant: D – Preclinical
EGFR L858R + EGFR T790M
NSCLC
CH7233163
Sensitive: D – Preclinical
EGFR L858R + EGFR T790M
NSCLC
rociletinib
Sensitive: D – Preclinical
EGFR L858R + EGFR T790M
NSCLC
osimertinib + BX795
Sensitive: D – Preclinical
EGFR L858R + EGFR T790M
NSCLC
H002
Sensitive: D – Preclinical
EGFR L858R + EGFR T790M
Lung Cancer
osimertinib + tipifarnib
Sensitive: D – Preclinical